Élodie Montaudon - Concepedia

Concepedia

Author

Élodie Montaudon

Institut Curie ORCID

Also Known As

E. Montaudon, Elodie Montaudon, Montaudon, Élodie, Élodie Montaudon

112

Publications

1.1K

Citations

16

H-Index

26

Concepts

All Affiliations

Institut Curie Inserm Université Paris Sciences et Lettres École Nationale Vétérinaire d'Alfort Oniris

ÉM

About

Élodie Montaudon is an author at Institut Curie specializing in medicine, vascular biology, and molecular pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	181
2	Engineering	1	1	40
3	Biomedical Engineering	1	1	40
4	Cell Biology	1	1	131
5	Immunology	1	1	10

Élodie Montaudon

×

20

Publications

1.1K

Citations

16

H-Index

	Year	Citations
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers Florence Coussy, Rania El Botty, Sophie Château‐Joubert, Science Translational Medicine	2020	132
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance Mingjun Bi, Zhao Zhang, Yi‐Zhou Jiang, Nature Cell Biology Lineage PlasticityMedicineGeneticsPhenotypic PlasticityGene Regulation	2020	131
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance Élodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd, Nature Communications	2020	122
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities Sunil Pancholi, Ricardo Ribas, Nikiana Simigdala, Oncogene	2020	88
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers Rania El Botty, Ludivine Morriset, Élodie Montaudon, Nature Communications	2023	84
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers Elisabetta Marangoni, Cécile Laurent, Florence Coussy, Clinical Cancer Research	2018	63
A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancer Florence Coussy, Leanne de Koning, Marion Lavigne, International Journal of Cancer	2019	55
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance Mandy Lawson, Natalie Cureton, Susana R�os, Cancer Research	2023	54
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts Florence Coussy, Marion Lavigne, Leanne de Koning, Theranostics	2020	53
Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy Pierre Foidart, Cassandre Yip, Jean Radermacher, Clinical Cancer Research	2018	52

Page 1